^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    TAVO412

    i
    Other names: TAVO412, Tavo-412
    Associations

    News

    Trials
    Company:
    Tavotek
    Drug class:
    EGFR inhibitor, c-MET inhibitor, VEGF inhibitor
    Related drugs:
    Associations

    News

    Trials
    6ms
    A trispecific antibody targeting EGFR/cMET/VEGF-A demonstrates multiple mechanisms of action to inhibit wild-type and mutant NSCLC animal models. (PubMed, Front Oncol)
    TAVO412 demonstrated more potent antitumor activity than amivantamab and cetuximab in NSCLC xenograft models using cell lines with varying levels of mutant and wild-type EGFR and cMET. Moreover, TAVO412 in combination with osimertinib, lazertinib, docetaxel, and radiotherapy, resulted in complete and durable regression of NSCLC xenograft tumors. These findings highlight TAVO412 as a promising therapeutic agent with multiple mechanisms of action and strong potential for synergistic combinations in NSCLC treatment.
    Preclinical • Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR wild-type
    |
    Erbitux (cetuximab) • Tagrisso (osimertinib) • docetaxel • Rybrevant (amivantamab-vmjw) • Lazcluze (lazertinib) • TAVO412
    9ms
    Developing transcriptomic biomarkers for TAVO412 utilizing next generation sequencing analyses of preclinical tumor models. (PubMed, Front Immunol)
    The biomarker model was further validated in the PDX data set and resulted in comparable accuracy. In implementing precision medicine by leveraging preclinical model data, a predictive transcriptomic biomarker empowered by next-generation sequencing was identified that could optimize the selection of patients that may benefit most from TAVO412 treatment.
    Preclinical • Journal • Next-generation sequencing
    |
    EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    TAVO412
    11ms
    A Study of TAVO412 in Patients with Cancer (TAVO412) (clinicaltrials.gov)
    P1, N=50, Recruiting, Tavotek Biotherapeutics
    New P1 trial
    |
    TAVO412
    1year
    A Study of TAVO412 in Patients with Cancer (clinicaltrials.gov)
    P1, N=50, Active, not recruiting, Tavotek Biotherapeutics | Recruiting --> Active, not recruiting | Trial completion date: Dec 2025 --> Jun 2026 | Trial primary completion date: Jun 2024 --> Dec 2025
    Enrollment closed • Trial completion date • Trial primary completion date • Metastases
    |
    EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    EGFR mutation • EGFR expression • EGFR overexpression • MET overexpression • MET mutation
    |
    TAVO412
    over2years
    A Study of TAVO412 in Patients With Cancer (clinicaltrials.gov)
    P1, N=50, Recruiting, Tavotek Biotherapeutics | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    EGFR mutation • EGFR expression • EGFR overexpression • MET overexpression • MET mutation
    |
    TAVO412
    over2years
    A Study of TAVO412 in Patients With Cancer (clinicaltrials.gov)
    P1, N=50, Not yet recruiting, Tavotek Biotherapeutics | Initiation date: Jan 2023 --> Apr 2023 | Trial primary completion date: Jan 2024 --> Jun 2024
    Trial initiation date • Trial primary completion date • Metastases
    |
    EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    EGFR mutation • EGFR expression • EGFR overexpression • MET overexpression • MET mutation
    |
    TAVO412
    3years
    A Study of TAVO412 in Patients With Cancer (clinicaltrials.gov)
    P1, N=50, Not yet recruiting, Tavotek Biotherapeutics
    New P1 trial
    |
    EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    EGFR mutation • EGFR expression • EGFR overexpression • MET overexpression • MET mutation
    |
    TAVO412